Bio-Rad Announces Life Science Group Management Changes
26 Aprile 2024 - 2:30PM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global
leader in life science research and clinical diagnostics products,
today announced the promotion of James J. Barry, currently Senior
Vice President of Global Manufacturing, to the position of
Executive Vice President and President of the Life Science Group,
effective May 1, 2024. He succeeds Dr. Simon May, who has announced
his decision to leave the company to pursue another professional
opportunity.
For the past two years, James Barry has been responsible for
Bio-Rad’s global manufacturing operations including quality,
planning, and continuous improvement initiatives across the
organization. Prior to his role within Global Manufacturing, he
oversaw Bio-Rad’s Quality Systems Division, which provides
third-party independent quality control materials and data
management software for hospitals and reference labs globally. Mr.
Barry joined Bio-Rad in 2017 from Beckman Coulter where he led
sales of the lab automation and genomics portfolio to academic,
pharmaceutical, and government customers. He holds a B.S. degree in
Mechanical Engineering from Rose Hulman Institute of Technology and
an MBA from Pepperdine University.
"We believe that Jim’s diverse business experience in senior
leadership roles, combined with his expertise in strategic
planning, operational excellence, and building high-performing
teams here at Bio-Rad, make him ideally suited to lead our global
life science business," said Norman Schwartz, Bio-Rad’s President
and Chief Executive Officer. "On behalf of the senior management
team, I would also like to thank Simon May for his valuable
contributions to Bio-Rad and to the Life Science Group,” Mr.
Schwartz continued. “During his tenure at Bio-Rad, Simon oversaw a
global team, numerous product launches, and the successful
integration of several acquisitions in support of the company’s
strategic objectives.”
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in
developing, manufacturing, and marketing a broad range of products
for the life science research and clinical diagnostics markets.
Based in Hercules, California, Bio-Rad operates a global network of
research, development, manufacturing, and sales operations with
approximately 8,000 employees and $2.7 billion in revenues in 2023.
Our customers include universities, research institutions,
hospitals, food safety and environmental quality laboratories, and
biopharmaceutical companies. Together, we develop innovative,
high-quality products that advance science and save lives. To learn
more, visit bio-rad.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240426570771/en/
Investor Contact: Edward Chung, Investor Relations
510-741-6104 ir@bio-rad.com
Media Contact: Anna Gralinska, Corporate Communications
510-741-6643 pr@bio-rad.com
Grafico Azioni Bio Rad Laboratories (NYSE:BIO)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Bio Rad Laboratories (NYSE:BIO)
Storico
Da Nov 2023 a Nov 2024